Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 301–400 of 1,006
Shi, L., Sheng, J., Wang, M., Luo, H., Zhu, J., Zhang, B., Liu, Z., & Yang, X. (2019) · Theranostics · doi:10.7150/thno.35131 · Cited by 101
“Importantly, administration of TGF-β blockade with EcN resulted in a significant improvement in the subcutaneous TME, demonstrated by a significant reduction in the level of immuno-inhibitory cytokines such as TGF-β and IL-10 both in the serum and tumor tissue homogenate (Figure 3F-H).”
BackgroundInfluentialGenetic and genomic basis of the mismatch repair system involved in Lynch syndrome
Tamura, K., Kaneda, M., Futagawa, M., Takeshita, M., Kim, S., Nakama, M., Kawashita, N., & Tatsumi‐Miyajima, J. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01494-y · Cited by 118
Bi, W. L., Nayak, L., Meredith, D. M., Driver, J., Du, Z., Hoffman, S. E., Li, Y. Y., Lee, E. Q., Beroukhim, R., Rinne, M. L., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab118 · Cited by 107
“31,32 Our group and others have demonstrated that the frequency of non-synonymous mutations is increased among high-grade meningiomas compared to grade 1 meningiomas, but there is a wide range of such events across high-grade meningiomas.”
Hyperprogression as a distinct outcome after immunotherapy
Fuentes‐Antrás, J., Provencio, M., & Díaz‐Rubio, E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.006 · Cited by 106
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
Xu, W., Liu, K., Chen, M., Sun, J., McCaughan, G. W., Lu, X., & Ji, J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919862692 · Cited by 107
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments
Katz, D., Palmerini, E., & Pollack, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_205423 · Cited by 111
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 109
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Wang, H.-C., Chan, L.-P., & Cho, S.-F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01084 · Cited by 99
Xie, C., Duffy, A. G., Brar, G. S., Fioravanti, S., Mabry‐Hrones, D., Walker, M., Bonilla, C. M., Wood, B. J., Citrin, D. E., Ramirez, E. M. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3624 · Cited by 107
“PDAC is characterized by a low tumor mutational burden (TMB), ranging from10 to 60 encoded neoantigens (41), and amedian TMBof 1.”
BackgroundImpact of high tumor mutational burden in solid tumors and challenges for biomarker application
McNamara, M. G., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102084 · Cited by 120
The role of AI technology in prediction, diagnosis and treatment of colorectal cancer
Yu, C., & Helwig, E. J. (2021) · Artificial Intelligence Review · doi:10.1007/s10462-021-10034-y · Cited by 117
Menon, D. R., Li, Y., Yamauchi, T., Osborne, D. G., Vaddi, P. K., Wempe, M. F., Zhai, Z., & Fujita, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111081 · Cited by 106
“PD-1/PD-L1-based cancer immunotherapy has, thus, resulted in remarkable clinical success for treating advanced cancers, such as melanoma [2], non-small cell lung cancer [3,4], bladder cancer [5] and others [4,6].”
BackgroundAlteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Wu, H., Chen, Y., Wang, Z.-X., Zhao, Q., He, M.-M., Wang, Y.-N., Wang, F., & Xu, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0737-3 · Cited by 108
Keshet, R., Lee, J. S., Adler, L. N., Iraqi, M., Ariav, Y., Lim, L. Q. J., Lerner, S., Rabinovich, S., Oren, R., Katzir, R., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0106-7 · Cited by 109
Burbach, B. J., O’Flanagan, S. D., Shao, Q., Young, K. M., Slaughter, J. R., Rollins, M. R., Street, T. J. L., Granger, V., Beura, L. K., Azarin, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24132-6 · Cited by 110
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Padella, A., di Rorà, A. G. L., Marconi, G., Ghetti, M., Martinelli, G., & Simonetti, G. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01228-0 · Cited by 113
“First, DDR dysfunction, and in particular HR deficiency, can increase the tumor mutational burden [93], which in turn can lead to the generation of neoantigens, and in particular mutation-associated neoantigens can enhance anticancer T cell activity [94].”
BackgroundSun, S., Liu, L., Zhang, J., Sun, L., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01732-z · Cited by 113
“This correlation has been validated by both retrospective and prospective studies, establishing TMB as a predictive biomarker for ICI response across various cancer types [18–20].”
Immunogenic Cell Death-Based Cancer Vaccines
Jin, M.-Z., & Wang, X.-P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697964 · Cited by 99
“that originally with low tumor burden and immunogenicity (17, 18).”
BackgroundChen, Y., Liu, Q., Chen, Z., Wang, Y., Yang, W., Hu, Y., Han, W., Zeng, H., Ma, H., Dai, J., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1192-1 · Cited by 107
Zhuo, M., Guan, Y., Yang, X., Hong, L., Wang, Y., Li, Z., Chen, R., Abbas, H. A., Chang, L., Gong, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0556 · Cited by 105
Jin, J., Yang, L., Liu, D., & Li, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035031 · Cited by 103
Wu, L., Ke, L., Zhang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602762 · Cited by 109
Programme of self-reactive innate-like T cell-mediated cancer immunity
Chou, C., Zhang, X., Krishna, C., Nixon, B. G., Dadi, S., Capistrano, K. J., Kansler, E. R., Steele, M., Han, J., Shyu, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04632-1 · Cited by 110
Güven, D. C., Kavgacı, G., Erul, E., Syed, M. P., Magge, T., Saeed, A., Yalçın, Ş., & Şahin, İ. H. (2024) · The Oncologist · doi:10.1093/oncolo/oyae013 · Cited by 113
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
Paré, L., Pascual, T., Seguí, E., Teixidó, C., González‐Cao, M., Galván, P., Rodríguez, A., González‐Farré, B., Cuatrecasas, M., Pineda, E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy335 · Cited by 108
D’Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., Lucia, M. D., Avalle, L., Vitale, R. L., Leuzzi, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10594-2 · Cited by 102
Milberg, O., Gong, C., Jafarnejad, M., Bartelink, I. H., Wang, B., Vicini, P., Narwal, R., Roskos, L., & Popel, A. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47802-4 · Cited by 94
Sato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
“One of the tumor intrinsic factors that is positively correlated with ICB response is the TMB in multiple cancer types [5], such as melanoma [22, 23], non-small-cell lung carcinoma [24], urothelial carcinoma [6].”
BackgroundAlessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97
Schweizer, M. T., Ha, G., Gulati, R., Brown, L. C., McKay, R. R., Dorff, T. B., Hoge, A. C. H., Reichel, J. B., Vats, P., Kilari, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00383 · Cited by 113
“One explanation for this lack of clinical efficacy may relate to relatively few tumor-specific antigens (ie, neoantigens) being expressed on prostate cancer cells, which is likely a consequence of the low somatic mutational burden in most prostate cancers.(5,6) Consistent with the hypothesis that mutational burden cor…”
BackgroundLabriola, M., Zhu, J., Gupta, R. T., McCall, S. J., Jackson, J., Kong, E., White, J. R., Cerqueira, G. C., Gerding, K., Simmons, J. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000319 · Cited by 103
In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy
Zhao, J., Ma, S., Xu, Y., Si, X., Yao, H., Huang, Z., Zhang, Y., Yu, H., Tang, Z., Song, W., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120542 · Cited by 99
Multiomics and spatial mapping characterizes human CD8 + T cell states in cancer
Naulaerts, S., Datsi, A., Borràs, D., Antoranz, A., Messiaen, J., Vanmeerbeek, I., Sprooten, J., Laureano, R. S., Govaerts, J., Panovska, D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1016 · Cited by 100
“To account for tumor type variability, we prioritized six TCGA cancers with gradually varying immunogenicity or antigenicity: highly immunogenic and highly antigenic (SKCM, lung adenocarcinoma or LUAD, and bladder carcinoma or BLCA), marginally immunogenic but low antigenic (breast carcinoma or BRCA), and low immunoge…”
MethodResultHendriks, L. E. L., Rouleau, É., & Besse, B. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.22 · Cited by 104
“It has been demonstrated that some cancer types have a better outcome with ICI treatment than would be expected from the TMB and for other tumors outcome is worse (17).”
BackgroundMethodMolecular profile of BRCA-mutated biliary tract cancers
Spizzo, G., Puccini, A., Xiu, J., Goldberg, R. M., Grothey, A. F., Shields, A. F., Arora, S. P., Khushman, M. M., Salem, M. E., Battaglin, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000682 · Cited by 99
“22 Looking at the impressive results of the POLO (Pancreas Cancer Olaparib Ongoing) trial, where patients with germline BRCA - mutant pancreatic cancer were successfully treated with the PARP inhibitor olaparib, 17 it is worthwhile to test the hypothesis that patients with BRCA - mutant BTC might…”
Glioblastoma vaccines: past, present, and opportunities
Xiong, Z., Raphael, I., Olin, M., Okada, H., Li, X., & Kohanbash, G. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2023.104963 · Cited by 90
“30 High mutational load is typically essential for successful ICB treatments in some types of cancers, 31,32 however, a recent study reported that very low TMB in recurrent GBM patients is associated with longer survival after ICB treatment.”
BackgroundNovel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours
Lowe, K. L., Cole, D., Kenefeck, R., OKelly, I., Lepore, M., & Jakobsen, B. K. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.001 · Cited by 95
“are almost completely absent from the tumour [8,9].”
BackgroundHo, W. W., Gomes-Santos, I. L., Aoki, S., Datta, M., Kawaguchi, K., Talele, N. P., Roberge, S., Ren, J. P., Liu, H., Chen, I. X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105323118 · Cited by 102
Atezolizumab for the treatment of breast cancer
Reddy, S. M., Carroll, E., & Nanda, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1732211 · Cited by 94
Tumor mutational burden in lung cancer: a systematic literature review
Willis, C., Fiander, M., Tran, D., Korytowsky, B., Thomas, J.-M., Calderon, F., Zyczynski, T. M., Brixner, D. I., & Stenehjem, D. D. (2019) · Oncotarget · doi:10.18632/oncotarget.27287 · Cited by 102
“Accordingly, TMB levels have been shown to correlate with objective response rates (ORR) during immunotherapy across a number of cancer types [8].”
BackgroundSurvival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen, N. D., Wang, M., Rubinstein, J. C., Olino, K. L., Clune, J. E., Ariyan, S., Cha, C. H., Weiss, S. A., Kluger, H. M., & Sznol, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000341 · Cited by 101
“7 27 However, other data show that immuno-therapy can still be effective against tumors with a paucity of mutations.”
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 102
Huang, X., Hu, M., Sun, T., Li, J., Zhou, Y., Yan, Y., Xuan, B., Wang, J., Xiong, H., Ji, L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.005 · Cited by 104
Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 100
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 96
“GBM harbors a low mutational 262 burden and exerts a potent immunosuppressive effect on the microenvironment (72).”
BackgroundCai, L., Liu, H., Huang, F., Fujimoto, J., Girard, L., Chen, J., Li, Y., Zhang, Y.-A., Deb, D., Stastny, V., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01842-7 · Cited by 103
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 99
Ding, D., Hu, H., Li, S., Zhu, Y., Shi, Y., Liao, M., Liu, J., Tian, X., Liu, A., & Huang, J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7796 · Cited by 102
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Perumal, D., Imai, N., Laganà, A., Finnigan, J. P., Melnekoff, D. T., Leshchenko, V. V., Solovyov, A., Madduri, D., Chari, A., Cho, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2309 · Cited by 97
Yoon, J. G., Kim, M. H., Jang, M., Kim, H., Hwang, H. K., Kang, C. M., Lee, W. J., Kang, B., Lee, C., Lee, M. G., et al. (2021) · Hepatology · doi:10.1002/hep.31862 · Cited by 97
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Shang, S., Liu, J., Verma, V., Wu, M., Welsh, J. W., Yu, J., & Chen, D. (2021) · 癌症:英文版 · doi:10.1002/cac2.12226 · Cited by 99
Affandi, A. J., Grabowska, J. A., Olesek, K., Venegas, M. L., Barbaria, A., Rodríguez, E., Mulder, P. P. G., Pijffers, H. J., Ambrosini, M., Kalay, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006186117 · Cited by 95
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 103
Clinical therapies and nano drug delivery systems for urinary bladder cancer
Jain, P., Kathuria, H., & Momin, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107871 · Cited by 89
Liu, J., Geng, R., Ni, S., Cai, L., Yang, S., Shao, F., & Bai, J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.018 · Cited by 102
“These scores reflect the proportion of immune and stromal components in 1052 Molecular Therapy: Nucleic Acids Vol. 27 March 2022 TME.”
BackgroundInfluentialCD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation
Boieri, M., Malishkevich, A., Guennoun, R., Marchese, E., Kroon, S., Trerice, K. E., Awad, M. E., Park, J. H., Iyer, S., Kreuzer, J., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20201963 · Cited by 91
“In addition, the antigen-directed immunotherapeutics, including neoantigen-based vaccines and engineered T cells, have limited applicability in an early cancer with a low mutational load (Yarchoan et al., 2017).”
BackgroundDevelopment of therapeutic vaccines for the treatment of diseases
Tian, Y., Hu, D., Li, Y., & Li, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00098-9 · Cited by 96
Precision cancer medicine: Concepts, current practice, and future developments
Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix‐Panabières, C., Staaf, J., Ploeger, C., Lassen, U., Tourneau, C. L., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13709 · Cited by 99
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, D., Lin, J., Yang, X., Long, J., Bai, Y., Yang, X., Mao, Y., Sang, X., Seery, S., & Zhao, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0730-9 · Cited by 90
“Alternative predictive markers are currently in the early exploratory phase [40, 41].”
BackgroundTargeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 92
“One emerging biomarker of the response to ICI is the tumour mutational burden (TMB), defined by the total number of mutations per coding area of the tumour genome [68].”
Backgroundda Silva, I. P., Ahmed, T., McQuade, J. L., Nebhan, C. A., Park, J., Versluis, J. M., Serra-Bellver, P., Khan, Y., Slattery, T., Oberoi, H. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01701 · Cited by 97
Ma, H., Chang, H., Yang, W., Lu, Y., Hu, J., & Jin, S. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1123-y · Cited by 100
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 99
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
“Indeed, all metastatic skin cancers have demonstrated significant responses to CPI treatment (9), and TMB analysis has shown that melanoma, SCC, BCC, and MCC, typically harbor mutational and antigenic loads at the higher end of the mutational spectrum (8, 9, 70–72).”
BackgroundClinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
Papadaki, M. A., Koutsopoulos, A. V., Tsoulfas, P. G., Lagoudaki, E. D., Aggouraki, D., Monastirioti, A. A., Koutoulaki, C., Apostolopoulou, C. A., Merodoulaki, A. C., Papadaki, C., et al. (2020) · Cancers · doi:10.3390/cancers12020376 · Cited by 91
“Even though BC is generally considered an immunologically “cold” tumor [16], accumulating evidence supports the role of different immunotherapy approaches in BC treatment [17].”
BackgroundPrognostic value and immunological role of PDCD1 gene in pan-cancer
Miao, Y., Wang, J., Li, Q., Quan, W., Wang, Y., Li, C., Wu, J., & Mi, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107080 · Cited by 97
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation
Borden, E. S., Buetow, K. H., Wilson, M. A., & Hastings, K. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836821 · Cited by 78
Bona, M. D., & Bakhoum, S. F. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1073 · Cited by 95
Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
Miyamoto, D. T., Mouw, K. W., Feng, F. Y.-C., Shipley, W. U., & Efstathiou, J. A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30693-4 · Cited by 88
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 92
“Recent studies suggest TMB as an efficient pan-cancer biomarker for ICI response.(16,32) Figure 3.”
BackgroundMillar, D. G., Ramjiawan, R. R., Kawaguchi, K., Gupta, N., Jiang, C., Zhang, S., Nojiri, T., Ho, W. W., Aoki, S., Jung, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0404-8 · Cited by 89
Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Cheng, L., López-Beltrán, A., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 92
“Tumor mutational burden (TMB) represents the most commonly used method to quantify mutational load, often reported as mutations/megabase (mut/Mb) [52]; in other terms, TMB count expresses the number of mutations reported in a megabase of tumor genomic territory [53].”
MethodHuo, Z., Li, C., Xu, X. Y., Ge, F., Wang, R., Wen, Y., Peng, H., Wu, X., Liang, H., Peng, G., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1848068 · Cited by 89
“TMB is a promising biomarker for predicting the response to immune checkpoint inhibitors (ICIs) of tumors.(9,105) In a clinical trial, TMB was more remarkably associated with response rate than the expression of PD-L1 by immunohistochemistry.”
BackgroundRole of autophagy on cancer immune escape
Duan, Y., Tian, X., Liu, Q., Jin, J., Shi, J., & Hou, Y. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00769-0 · Cited by 87
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 89
“TMB was observed to be relatively high in melanoma and CRC, and low in pancreatic cancer [203].”
BackgroundTranslation of AI into oncology clinical practice
El Naqa, I., Karolak, A., Luo, Y., Folio, L., Tarhini, A. A., Rollison, D., & Parodi, K. (2023) · Oncogene · doi:10.1038/s41388-023-02826-z · Cited by 81
“In terms of genomic sequencing, promising immunotherapeutic biomarkers included the tumor mutational burden (TMB) [70], aneuploidy (also known as somatic copy number alterations, SCNAs) [71], neoantigen prediction [72], HLA-I [72, 73] genotypes, T-cell repertoire [74], and germline genetic variations [75].”
BackgroundEntinostat induces antitumor immune responses through immune editing of tumor neoantigens
Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84
Yuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Gillece, J. D., Folkerts, M., Reining, L., et al. (2020) · The Oncologist · doi:10.1002/onco.13583 · Cited by 91
“Whereas breast cancer has low TMB compared with other immunogenic cancers, such as melanoma and lung cancer that have shown good responses to PD-1 inhibitors [51], TNBC has relatively higher TMB than other types of breast cancer [52].”
BackgroundEvasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
Zhu, M., Huang, Y., Bender, M. E., Girard, L., Kollipara, R. K., Eglenen-Polat, B., Naito, Y., Savage, T. K., Huffman, K. E., Koyama, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2808 · Cited by 87
A novel era of cancer/testis antigen in cancer immunotherapy
Meng, X., Sun, X., Liu, Z., & He, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107889 · Cited by 88
Ribeiro, R., Carvalho, M. J., Gonçalves, J., & Moreira, J. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.903065 · Cited by 90
“higher TMB values showed an increased objective response rate (ORR) when treated with immunotherapies (Yarchoan et al., 2017; Loibl et al., 2019).”
BackgroundImmune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Federico, P., Petrillo, A., Giordano, P., Bosso, D., Fabbrocini, A., Ottaviano, M., Rosanova, M., Silvestri, A., Tufo, A., Cozzolino, A., et al. (2020) · Cancers · doi:10.3390/cancers12103025 · Cited by 89
Wen, Q., Yang, Z., Dai, H., Feng, A., & Li, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620246 · Cited by 95
Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., Yin, X., Ge, M., Xiang, X., Ying, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02605-9 · Cited by 78
“However, the objective response rate (ORR) in the all-comer population is less than 20% in most tumor types [1].”
BackgroundMok, T. S. K., Lopes, G., Cho, B. C., Kowalski, D. M., Kasahara, K., Wu, Y.-L. L. C., de Castro, G., Turna, H. Z., Cristescu, R., Aurora-Garg, D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.011 · Cited by 88
Sarkar, O. S., Donninger, H., Rayyan, N. A., Chew, L. C., Stamp, B. F., Zhang, X., Whitt, A. G., Li, C., Hall, M. B., Mitchell, R. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3736 · Cited by 86
“One of the best predictors of clinical responses to anti–PD-1 Ab is the presence of increased tumor somatic mutations (3).”
Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy
Li, G., Mahajan, S., Ma, S., Jeffery, E. D., Zhang, X., Bhattacharjee, A., Venkatasubramanian, M., Weirauch, M. T., Miraldi, E. R., Grimes, H. L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade2886 · Cited by 85
“Although immune checkpoint blockade (ICB) has become the frontline clinical treatment in patients with high mutational burden, such therapies are not used in many cancers with low mutation burden, such as glioma and leukemia ( 7 , 8 ).”
BackgroundLifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 90
Engels, E. A. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15495 · Cited by 85
Hamid, O., Molinero, L., Bolen, C. R., Sosman, J. A., Muñoz-Couselo, E., Kluger, H. M., McDermott, D. F., Powderly, J. D., Sarkar, I., Ballinger, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3488 · Cited by 80
Immunotherapy in Malignant Pleural Mesothelioma
de Gooijer, C. J., Borm, F. J., Scherpereel, A., & Baas, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00187 · Cited by 90
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression
Zhou, X. A., Zhou, J., Zhao, L., Yu, G., Zhan, J., Shi, C., Yuan, R., Wang, Y., Chen, C., Zhang, W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004570117 · Cited by 84
“The other important question in the field is that resistance and low response rate limit the efficiency of immunotherapy despite its status as one of the most promising treatment options for cancer (20, 21).”
BackgroundDai, X., Gao, Y., & Wei, W. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.002 · Cited by 85
Direct Detection and Quantification of Neoantigens
Wang, Q., Douglass, J., Hwang, M. S., Hsiue, E. H.-C., Mog, B. J., Zhang, M., Papadopoulos, N., Kinzler, K. W., Zhou, S., & Vogelstein, B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0107 · Cited by 72
“MANAs are critical inducers of T cell–mediated anticancer immune response (1, 24).”
BackgroundRaphael, I., Kumar, R., McCarl, L. H., Shoger, K. E., Wang, L., Sandlesh, P., Sneiderman, C. T., Allen, J., Zhai, S., Campagna, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637146 · Cited by 86
“Nonetheless, evidence supporting the efficacy of IC immunotherapy in glioma remains insufficient (11).”
BackgroundThe Immunology of Hepatocellular Carcinoma
Lawal, G., Xiao, Y., Rahnemai‐Azar, A. A., Tsilimigras, D. I., Kuang, M., Bakopoulos, A., & Pawlik, T. M. (2021) · Vaccines · doi:10.3390/vaccines9101184 · Cited by 91
Tang, B., Yan, R., Zhu, J., Cheng, S., Kong, C., Chen, W., Fang, S., Wang, Y., Yang, Y., Qiu, R., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64654 · Cited by 87
“Cancer immunotherapy functions a different mechanism than traditional radiotherapy, chemotherapy or targeted therapy, bringing new hope to cancer patients [75].”
Background
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.